APA (7th ed.) Citation

Van Gorp, T., Cibula, D., Lv, W., Backes, F., Ortaç, F., Hasegawa, K., . . . Buchanan, T. (2024). ENGOT-en11/GOG-3053/KEYNOTE-B21: A randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Annals of Oncology, 35(11), 968. https://doi.org/10.1016/j.annonc.2024.08.2242

Chicago Style (17th ed.) Citation

Van Gorp, T., et al. "ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-blind, Phase III Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy with or Without Radiotherapy in Patients with Newly Diagnosed, High-risk Endometrial Cancer." Annals of Oncology 35, no. 11 (2024): 968. https://doi.org/10.1016/j.annonc.2024.08.2242.

MLA (9th ed.) Citation

Van Gorp, T., et al. "ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-blind, Phase III Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy with or Without Radiotherapy in Patients with Newly Diagnosed, High-risk Endometrial Cancer." Annals of Oncology, vol. 35, no. 11, 2024, p. 968, https://doi.org/10.1016/j.annonc.2024.08.2242.